Literature DB >> 2265110

Osteoblast stimulation in multiple myeloma lacking lytic bone lesions.

R Bataille1, D Chappard, C Marcelli, J F Rossi, P Dessauw, P Baldet, J Sany, C Alexandre.   

Abstract

The reasons why some patients with multiple myeloma (MM) do not develop severe bone loss, or even develop sclerotic bone lesions, remain unclear. In order to answer this question at the cellular and tissue level, we evaluated the histological bone condition of 10 patients with MM who never developed lytic bone lesions during the course of their disease (including two patients with sclerotic MM). Myeloma-induced bone changes in the close vicinity of myeloma cells were evaluated by quantitative histology (bone histomorphometry). All 10 patients presented a significantly increased osteoblastic activity. This was associated with an increased bone resorption in seven of the 10 cases. Three patients had a pure osteoblastic presentation. These features were the reverse of the pattern observed in seven patients with lytic bone lesions: increased bone resorption with decreased bone formation. Almost all of these 10 patients showing excessive osteoblastic activity had increased serum bone gla protein levels, a specific marker of bone formation. Finally, 90% of these patients were lambda MM (70% of them were IgG lambda MM), an immunoglobulin subtype previously associated with the sclerotic MM variants. In conclusion, a subset of patients with MM never develop severe bone loss because of the stimulation of osteoblastic activity. These patients belong to the same family as osteosclerotic MM, presenting more frequently the IgG type and lambda subtype.

Entities:  

Mesh:

Year:  1990        PMID: 2265110     DOI: 10.1111/j.1365-2141.1990.tb07904.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

2.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 3.  Tumor-host cell interactions in the bone disease of myeloma.

Authors:  Jessica A Fowler; Claire M Edwards; Peter I Croucher
Journal:  Bone       Date:  2010-07-13       Impact factor: 4.398

4.  Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

Authors:  Scott A Ely; Daniel M Knowles
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

5.  Osteolytic lesions marker in multiple myeloma.

Authors:  Irena Djunic; Ivo Elezovic; Milica Marinkovic; Nada Suvajdzic-Vukovic; Dragica Tomin; Gradimir Jankovic; Jelena Bila; Darko Antic; Ana Vidovic; Borka Neskovic; Dragica Nikolic-Vukosavljevic
Journal:  Med Oncol       Date:  2010-02-02       Impact factor: 3.064

6.  Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo.

Authors:  Kenneth M Kozloff; Luisa Quinti; Somying Patntirapong; Peter V Hauschka; Ching-Hsuan Tung; Ralph Weissleder; Umar Mahmood
Journal:  Bone       Date:  2008-10-22       Impact factor: 4.398

7.  Multiple Myeloma With Mixed Lytic and Blastic Bone Lesions With Lymphadenopathy: Rare Manifestation of a Common Disease-Case Presentation and Literature Review.

Authors:  Setu Patolia; Frances Schmidt; Swati Patolia; Neerja Gulati; Perwaiz Muhammad; Dharani Narendra; Danilo Enriquez; Joseph Quist
Journal:  World J Oncol       Date:  2012-04-23

8.  Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.

Authors:  Bing Ji; Paul G Genever; Ronald J Patton; Michael J Fagan
Journal:  Int J Numer Method Biomed Eng       Date:  2014-05-09       Impact factor: 2.747

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.